Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.35 |
| ▸ | ARG2 | P78540 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16625962 | 1.00 | ARG1 (0.35) | ARG1ARG2DPP4DPP8DPP9 | |
| SCHEMBL16625965 | 1.00 | ARG1 (0.35) | ARG1ARG2DPP4DPP8DPP9 | |
| SCHEMBL14131190 | 0.90 | ROCK2 (0.37) | DPP4DPP8DPP9SIGMAR1HRH3 | |
| SCHEMBL13519612 | 0.89 | ARG1 (0.38) | ARG1ARG2SIGMAR1NOS3NOS1 | |
| SCHEMBL13171644 | 0.84 | GBA1 (0.35) | SIGMAR1PIK3CDGBA1 | |
| SCHEMBL16625897 | 0.82 | ARG1 (0.35) | ARG1ARG2NOS3NOS1NOS2 | |
| SCHEMBL18575434 | 0.81 | GNAI3 (0.40) | ARG1ARG2SIGMAR1NOS3NOS1 | |
| SCHEMBL23103231 | 0.80 | PIK3CD (0.47) | DPP4DPP8DPP9HRH3PIK3CD | |
| SCHEMBL12041121 | 0.80 | PIK3CD (0.47) | DPP4DPP8DPP9HRH3PIK3CD | |
| SCHEMBL23103243 | 0.80 | PIK3CD (0.47) | DPP4DPP8DPP9HRH3PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024147972-A2 | DNA POLYMERASE THETA INHIBITORS CONTAINING NON-SATURATED 5-MEMBERED HETEROCYCLIC RINGS AND USE THEREOF | THOMAS JEFFERSON UNIVERSITY (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2023196342-A1 | α4β1/7 INTEGRIN LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230265091-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE | LIEBER INSTITUTE, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265091-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE | LIEBER INSTITUTE, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11370773-B1 | Inhibiting human integrin (alpha-4) (beta-7) | MORPHIC THERAPEUTIC, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| WO-2021076902-A1 | INHIBITING HUMAN INTEGRIN α 4 β 7 | MORPHIC THERAPEUTIC, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021076890-A1 | INHIBITING HUMAN INTEGRIN α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| US-10669269-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20180086758-A1 | SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086758-A1 | SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20160002232-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-9174981-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140349989-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA (US) | 2014-11-27 | — | — | US | disclosed |
| US-8865726-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-8841455-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as cFMS inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130274244-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2013-10-17 | — | — | US | disclosed |
| WO-2012177782-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| US-20120258952-A1 | Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2012082689-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274244-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | MUSK, FGFR1, FRK | ARG1 817/4885ARG2 1202/4885DPP4 2125/4885 |
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MTOR, RICTOR, EIF4EBP1 | ARG1 1716/4885ARG2 1997/4885DPP4 4065/4885 |
| US-10669269-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | MUSK, FGFR1, PDGFRA | ARG1 774/4885ARG2 1100/4885DPP4 2356/4885 |
| US-20140349989-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD4, CD47 | ARG1 152/4885ARG2 68/4885DPP4 193/4885 |
| US-11370773-B1 | Inhibiting human integrin (alpha-4) (beta-7) | ITGB7, ITGB4, ITGA4 | ARG1 4026/4885ARG2 4665/4885DPP4 101/4885 |
| US-20180086758-A1 | SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | LTK, MUSK, FGFR1 | ARG1 866/4885ARG2 1057/4885DPP4 2139/4885 |
| US-20230265091-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE | POLR2E, POLR2H, POLRMT | ARG1 4730/4885ARG2 4607/4885DPP4 1854/4885 |
| US-20120258952-A1 | Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors | AFF1, FLI1, F3 | ARG1 357/4885ARG2 1323/4885DPP4 1431/4885 |
| US-20160002232-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | MUSK, TYRO3, IRAK3 | ARG1 1038/4885ARG2 1217/4885DPP4 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.